All News
Bariatric Surgery Improves Rheumatoid Arthritis Outcomes
Obesity is a modest risk factor for rheumatoid arthritis (RA) onset. More importantly, obese patients have significanty lower treatment responses to DMARDs and biologics, making them harder to treat than your average RA patient.
Read Article
Herpes Zoster Increases the Risk of Stroke and MI
At the 2015 ACR annual meeting in San Francisco, Len Calabrese, DO, of the Cleveland Clinic, gave a plenary session talk linking "shingles" infection to an increased risk of CVA (
Read Article
Can Gout and Rheumatoid Arthritis Coexist?
German investigators studied 100 RA patients with a uric acid > 6 mg/dl and assessed them for MSU crystal deposit with dual energy computed tomography (DECT) of both feet and hands.
Read Article
RA Guidelines, Methotrexate and Mortal Risks in Gout: November 2015 top social media news
Here's what you may have missed: in November 2015, RheumNow published 80 tweets on news, research and teaching points that impact the rheumatology community. We had a reach (impressions) of 79,100, 79 mentions, and over 3399 visits to RheumNow.com to check out what we publish.
Read Article
DRIVE Trial: Denosumab and Methotrexate Prevent Joint Erosions
Joint erosions in RA result from a complex process with multiple contributing mechanisms. One of those mechanisms involves RANK receptor activation by RANKL leading to osteoclast differentiation, activation and survival.
Read Article
Azathioprine Adverse Events Associated with TPMT Polymorphisms
Azathioprine (AZA) is widely used in the treatment of several autoimmune diseases. Its use and optimal dosing may be limited by adverse drug reactions (ADRs). Thiopurine S-methyltransferase (TPMT) is an important enzyme involved in AZA metabolism.
Read Article
In RA TNF-Inhibitors Prove To Be Durable Choice
Patients with rheumatoid arthritis (RA) were less likely to discontinue their first biologic when that treatment was a tumor necrosis factor (TNF) inhibitor than if it was a non-TNF biologic, and especially if treatment was initiated prior to 2005.
Read ArticleRituximab's Efficacy May Be Correlated with CD4 T Cell Counts
Rituximab (RTX) is highly effective at B cell depletion and this may be one of several hypothetical ways in which the drug works. B cell numbers (measured as CD19+ B cells) plummet rapidly after the first infusion and stay down for 6-12 months.
Read Article
Prudent Diet Reduces Risk of RA and Gout
The 2015 ACR meeting in San Francisco highlighted several studies wherein dietary patterns predicted a reduced risk of both rheumatoid arthritis (RA) and gout.
Read Article
The Rising Price of Dermatologic Drugs
Containment of health care costs was a primary goal of the Patient Protection and Affordable Care Act. But there is little evidence of success in curbing the rising price of prescription drugs. As such, many medications are unaffordable to those who need them.
Read Article
Fertility in RA Linked to Disease Activity, NSAIDs and Prednisone
Brouwer and colleagues from the University Medical Center Rotterdam in The Netherlands have studied the issue of infertility in a cohort of RA patients followed prospectively.
Read Article
DSB: ACR 2015 Safety Reports
The following is a compilation of abstracts presented at the 2015 Annual ACR meeting in San Francisco. These were chosen on the basis of impact, quality and safety message.
Read Article
Power Doppler Ultrasound Detects Early Synovitis Change in APPRAISE Study
While new recommendations suggest early aggressive management of rheumatoid arthritis, our ability to assess treatment response is limited to clinical and laboratory assessment.
Read Article
EU Endorses Biosimilar Etanercept (SB4) from Samsung/Biogen
Reuters today reported that a copy of the blockbuster biotech drug Enbrel (SB4) was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light from the continent's regulators.
Read Article
Opioid Use Ups the Risk of Hospitalized Infections in Rheumatoid Arthritis
Researchers from Vanderbilt University have studied the issue of opioid use in rheumatoid arthritis (RA) and whether this influences infection risk.
Read Article
SB4 - A Second Biosimilar Up For Review in Europe
A biosimilar of etanercept (Enbrel) made by the South Korean company Samsung Bioepis is under consideration by regulators in the European Union. Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, is taking aim with its version of etanercept.
Read Article
Alcohol and Methotrexate - What Do You Advise?
What are your rules on methotrexate and alcohol use? How about casual, social or occasional alcohol use? If one alcoholic beverage is ok, what about 2, 3 or six while taking MTX?
Read Article
Surviving Infection on DMARDs or Biologics
Sepsis is a dangerous and potentially fatal consequence of serious infections (SIE), particularly in susceptible populations such as the elderly and immunosuppressed. Published evidence points toward the potential role of TNF in development of sepsis.
Read Article
Are Guidelines Worth the Cost?
A thoughtful perspective on the purpose, focus and cost of guideline efforts in rheumatology has been published in the journal Rheumatology.
Is Baricitinib Really Better Than Adalimumab in RA: Trial Results Reviewed
Dr. Peter Taylor and colleagues presented their results of the 52-week BEAM trial wherein baricitinib (a JAK 1, 2 inhibitor) was compared to adalimumab in both clinical and radiographic outcomes. This was the most viewed abstract online at the ACR website.
Read Article